Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Daiichi Sankyo
AstraZeneca
Covington
Novartis
Teva
Merck
Federal Trade Commission
Dow

Generated: February 19, 2018

DrugPatentWatch Database Preview

TRILIPIX Drug Profile

« Back to Dashboard

When do Trilipix patents expire, and when can generic versions of Trilipix launch?

Trilipix is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has nineteen patent family members in eleven countries.

The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.
Drug patent expirations by year for TRILIPIX
Pharmacology for TRILIPIX

US Patents and Regulatory Information for TRILIPIX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-001 Dec 15, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-002 Dec 15, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TRILIPIX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 9/2/2009
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 9/1/2009

International Patents for TRILIPIX

Supplementary Protection Certificates for TRILIPIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0009 Belgium ➤ Sign Up PRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214
2017 00030 Denmark ➤ Sign Up PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Accenture
Cipla
Cerilliant
Julphar
Farmers Insurance
Medtronic
QuintilesIMS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot